245 related articles for article (PubMed ID: 24971740)
1. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.
Huang F; Mazin AV
PLoS One; 2014; 9(6):e100993. PubMed ID: 24971740
[TBL] [Abstract][Full Text] [Related]
2. New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
Shkundina IS; Gall AA; Dick A; Cocklin S; Mazin AV
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34208492
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase.
Huang F; Mazina OM; Zentner IJ; Cocklin S; Mazin AV
J Med Chem; 2012 Apr; 55(7):3011-20. PubMed ID: 22380680
[TBL] [Abstract][Full Text] [Related]
4. Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Ward A; Dong L; Harris JM; Khanna KK; Al-Ejeh F; Fairlie DP; Wiegmans AP; Liu L
Bioorg Med Chem Lett; 2017 Jul; 27(14):3096-3100. PubMed ID: 28545975
[TBL] [Abstract][Full Text] [Related]
5. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening.
Huang F; Motlekar NA; Burgwin CM; Napper AD; Diamond SL; Mazin AV
ACS Chem Biol; 2011 Jun; 6(6):628-35. PubMed ID: 21428443
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways.
Schürmann L; Schumacher L; Roquette K; Brozovic A; Fritz G
Cancer Lett; 2021 Nov; 520():361-373. PubMed ID: 34389435
[TBL] [Abstract][Full Text] [Related]
8. A small-molecule inhibitor of the DNA recombinase Rad51 from
Vydyam P; Dutta D; Sutram N; Bhattacharyya S; Bhattacharyya MK
J Biol Chem; 2019 May; 294(20):8171-8183. PubMed ID: 30936202
[TBL] [Abstract][Full Text] [Related]
9. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
[TBL] [Abstract][Full Text] [Related]
10. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
11. The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma.
Chen Q; Cai D; Li M; Wu X
Oncol Rep; 2017 Aug; 38(2):767-774. PubMed ID: 28627709
[TBL] [Abstract][Full Text] [Related]
12. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
13. A novel UCHL
Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
[TBL] [Abstract][Full Text] [Related]
14. RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.
Wiegmans AP; Miranda M; Wen SW; Al-Ejeh F; Möller A
Oncotarget; 2016 Sep; 7(37):60087-60100. PubMed ID: 27507046
[TBL] [Abstract][Full Text] [Related]
15. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin.
Koehn H; Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2007 Apr; 18(4):419-25. PubMed ID: 17351394
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein.
Ferguson PJ; Vincent MD; Koropatnick J
J Pharmacol Exp Ther; 2018 Jan; 364(1):46-54. PubMed ID: 29061656
[TBL] [Abstract][Full Text] [Related]
19. Electrophilic fatty acids impair RAD51 function and potentiate the effects of DNA-damaging agents on growth of triple-negative breast cells.
Asan A; Skoko JJ; Woodcock CC; Wingert BM; Woodcock SR; Normolle D; Huang Y; Stark JM; Camacho CJ; Freeman BA; Neumann CA
J Biol Chem; 2019 Jan; 294(2):397-404. PubMed ID: 30478172
[TBL] [Abstract][Full Text] [Related]
20. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]